Teva Pharmaceutical Industries (FRA:TEV) Interest Expense: €-777 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TEV Teva Pharmaceutical Industries Ltd FRA:TEV
58 GF Score
Price €27.50
GF Value €17.39
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Interest Expense?

Teva Pharmaceutical Industries FRA:TEV +0.73% 58 Interest Expense is €-777 Mil as of Mar. 2026. GuruFocus rates FRA:TEV with a GF Score™ of 58/100 and a GF Value™ of €17.39 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Teva Pharmaceutical Industries's interest expense for the three months ended in Mar. 2026 was € -174 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-777 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Teva Pharmaceutical Industries's Operating Income for the three months ended in Mar. 2026 was € 657 Mil. Teva Pharmaceutical Industries's Interest Expense for the three months ended in Mar. 2026 was € -174 Mil. Teva Pharmaceutical Industries's Interest Coverage for the quarter that ended in Mar. 2026 was 3.78. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Teva Pharmaceutical Industries  (FRA:TEV) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Teva Pharmaceutical Industries's Interest Expense for the three months ended in Mar. 2026 was €-174 Mil. Its Operating Income for the three months ended in Mar. 2026 was €657 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €12,365 Mil.

Teva Pharmaceutical Industries's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*656.535/-173.865
=3.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Teva Pharmaceutical Industries Interest Expense Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Interest Expense Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -788.54 -877.92 -943.59 -956.91 -782.26

Teva Pharmaceutical Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -196.10 -176.00 -178.07 -249.37 -173.87
FRA:TEV
58GF Score
Teva Pharmaceutical Industries Ltd FRA:TEV
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-777 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-777 Mil mean?
Teva Pharmaceutical Industries (FRA:TEV) has a Interest Expense of €-777 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Teva Pharmaceutical Industries and its competitors.
Is Teva Pharmaceutical Industries' Interest Expense too high?
Teva Pharmaceutical Industries' current Interest Expense is €-777 Mil. Overall, Teva Pharmaceutical Industries has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Interest Expense compare to ZTS and UTHR?
Teva Pharmaceutical Industries' Interest Expense of €-777 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Teva Pharmaceutical Industries and its competitors. Teva Pharmaceutical Industries's current Interest Expense is €-777 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (FRA:TEV) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.39, compared to a current price of €27.50 — trading 58.1% above its estimated fair value. The current Interest Expense is €-777 Mil. Teva Pharmaceutical Industries' overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Teva Pharmaceutical Industries (FRA:TEV), the current Interest Expense is €-777 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (FRA:TEV) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of €27.50 is trading 58.1% above its estimated GF Value™ of €17.39. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for FRA:TEV:

  • Interest Expense: €-777 Mil
  • GF Value™: €17.39 vs. price of €27.50 (58.1% above fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the FRA:TEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
58GF Score

Get the complete analysis for FRA:TEV

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.50
Price
€17.39
GF Value